Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Attention deficit hyperactivity disorder (ADHD) is the most common behavior disorder, with
the prevalence of 3% to 6% in children and adolescents. The patients' academic achievements,
professions and social livings are impaired. Comorbid antisocial behavior, substance abuse
and delinquency burden family and society. Stimulants used to be the first line drug. But the
medication compliance is poor because of strict drug administration. Atomoxetine is a new
non-stimulant drug, which can effectively improve ADHD symptoms. But it achieves effect
slowly, the drug responses differ significantly, and side effects interfere compliance. Since
genetic factors is the most important cause for different drug responses, this project
studies candidate genes potentially associated with atomoxetine medication, with the aim to
find 2 to 3 gene polymorphisms influencing the drug response of ADHD. The study adopts cohort
design. A sample of more than 100 ADHD cases with atomoxetine medication is to be collected.
The rapid genotyping of large sample depends on high-through laboratory. New statistic method
is to be used to improve the sensitivity of the target gene detection. There has been no such
report in country and overseas. This project will provide basic information for forecasting
drug response, improving clinical effects, tolerance and long-term compliance.